The API sector fluctuated and weakened, and the East Asian pharmaceutical industry hit a standstill, and Sunflower, Aoxiang Pharmaceuticals, Orient, Minova, Sunda Biotech, and Saito Biotech followed suit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.